On May 29, Promedius announced that it has been selected as part of a cohort of 20 promising companies for the MedTech Innovator Asia Pacific accelerator program.

More than 400 companies applied to this year's program since March; 60 companies were selected from the first round to participate in a second round of pitches in Singapore. During this process, Promedius pitched its chest radiographs-based osteoporosis screening AI solution and was selected to the final cohort of 20 companies.

The 20 selected companies will receive various forms of support from global healthcare companies and investors in the medtech industry, including mentoring, networking, and business modeling. They will also be provided with connections to partners who can help them commercialize in the Asia-Pacific region to enhance their international expansion capabilities.

"This cohort represents a diverse range of technologies and cutting-edge innovations from 10 countries," said Fredrik Nyberg, Managing Director of MedTech Innovator Asia Pacific. "We look forward to seeing the startups' technologies help transform patients' lives not only in the region, but globally."

"We are excited to be one step closer to our vision of enabling Healthy Aging through AI through this program," said Hyunjin Bae, CEO of Promedius. "As an AI company specializing in bone health, we look forward to making a greater impact through our global reach."

MedTech Innovator Asia Pacific Accelerator 20 cohort (출처: MedTech Innovator Asia Pacific Linkedin)